Phase I/II Study to Determine the Maximum Tolerated Dose and Activity of the Combination of Romidepsin and Carfilzomib in Relapsed or Refractory Peripheral T-cell Lymphoma
Phase of Trial: Phase I/II
Latest Information Update: 02 May 2018
At a glance
- Drugs Carfilzomib (Primary) ; Romidepsin (Primary)
- Indications Peripheral T-cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- Acronyms RomiCar
- 04 Aug 2016 Planned End Date changed from 1 Feb 2016 to 13 Jul 2020.
- 04 Nov 2015 Accrual till date is 5% according to United Kingdom Clinical Research Network record
- 01 Nov 2015 Accrual till date is 3% according to United Kingdom Clinical Research Network record.